Please assess the completion status of the following clinical trial:

Trial Title: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have previously participated in a Phase IIb or Phase III study~* Must have received at least one dose of TMC435 in that study~* Has completed the last post-therapy follow-up visit of the previous (LPVPS) study~Exclusion Criteria:~* Must be currently enrolled or plan to enroll in another study with an investigational drug or invasive investigational medical device~* Have received antiviral or immunomodulating treatment, including therapeutic vaccines, for hepatitis C virus (HCV) between LPVPS and the screening visit of present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: TMC 435 - Patients With SVR at LPVPS (Type: OTHER): Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.
- Group 2: TMC 435 - Patients With No SVR at LPVPS (Type: OTHER): Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).